Yuen-Yi Tseng, Ph.D. - Publications

Affiliations: 
2013 Molecular, Cellular, Developmental Biology and Genetics University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Genetics, Cell Biology, Molecular Biology

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, Zhang F. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nature Communications. 13: 1606. PMID 35338135 DOI: 10.1038/s41467-022-29205-8  0.319
2022 Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. PMID 35084050 DOI: 10.1002/pros.24305  0.313
2020 Tseng Y, Keskula P, Deasy R, Hong A, Chatterji P, Vazquez F, Bass A, Hare BV, Sandak D, Ligon K, Boehm J. Abstract PR09: A systematic approach to create patient-derived models of rare tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Pr09  0.505
2019 Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, ... ... Tseng YY, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. PMID 30971823 DOI: 10.1038/S41586-019-1102-X  0.456
2019 Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications. 10: 1617. PMID 30962421 DOI: 10.1038/S41467-019-09277-9  0.398
2019 Tseng YY, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Current Opinion in Genetics & Development. 54: 33-40. PMID 30928774 DOI: 10.1016/J.Gde.2019.02.007  0.5
2019 Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, et al. Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. Elife. 8. PMID 30860482 DOI: 10.7554/Elife.44161  0.408
2019 Tseng YY, Bagchi A. Engineering Large Genomic Rearrangement in Mouse Embryonic Stem Cell for Cancer Gene Discovery. Methods in Molecular Biology (Clifton, N.J.). 1907: 197-212. PMID 30543002 DOI: 10.1007/978-1-4939-8967-6_16  0.745
2018 Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, et al. A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30397176 DOI: 10.1158/1078-0432.Ccr-18-0372  0.395
2018 Hong AL, Tseng Y, Kynnap BD, Doshi MB, Wala J, Sandoval G, Church AJ, Mullen E, Kadoch C, Roberts CWM, Beroukhim R, Boehm JS, Hahn WC. Abstract B18: Modeling renal medullary carcinomas identifies druggable vulnerabilities in SMARCB1-deficient cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-B18  0.525
2018 Ben-David U, Ha G, Tseng Y, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Abstract 1028: Patient-derived xenografts undergo mouse-specific tumor evolution Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1028  0.342
2018 De Smet F, Tseng Y, Ramkissoon S, Ramkissoon L, Pelton K, Luna RF, Panovska D, Schoolcraft K, Watkinson F, Bilton S, Hung V, Chow K, Geduldig J, Becker S, Jones R, et al. TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi271-vi271. DOI: 10.1093/Neuonc/Noy148.1126  0.496
2017 Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Patient-derived xenografts undergo mouse-specific tumor evolution. Nature Genetics. PMID 28991255 DOI: 10.1038/Ng.3967  0.503
2017 Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, Tseng YY, Yoon CH, Boehm JS, Lander ES, Zhang F. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. PMID 28792927 DOI: 10.1038/Nature23451  0.416
2017 Hong AL, Tseng Y, Kynnap BD, Doshi MB, Sandoval G, Oh C, Sayeed A, Shubhroz G, Church AJ, Keskula P, Peng A, Clemons PA, Tsherniak A, Vazquez F, Rodriguez-Galindo C, et al. Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B17  0.464
2017 Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Alkhairy S, Oh C, Peng A, Deasy R, Sayeed A, Ronning P, et al. Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models Cancer Research. 77: 1953-1953. DOI: 10.1158/1538-7445.Am2017-1953  0.501
2017 Tashiro K, Tseng Y, Konety B, Bagchi A. MP99-18 ROLE OF LONG NON-CODING RNA PVT1 IN REGULATING MYC IN HUMAN CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3104  0.721
2016 Giannikou K, Malinowska IA, Pugh TJ, Yan R, Tseng YY, Oh C, Kim J, Tyburczy ME, Chekaluk Y, Liu Y, Alesi N, Finlay GA, Wu CL, Signoretti S, Meyerson M, et al. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. Plos Genetics. 12: e1006242. PMID 27494029 DOI: 10.1371/Journal.Pgen.1006242  0.362
2016 Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications. 7: 11987. PMID 27329820 DOI: 10.1038/Ncomms11987  0.507
2016 Sarver AL, Murray CD, Temiz NA, Tseng YY, Bagchi A. MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 26889781 DOI: 10.1080/15384101.2016.1149660  0.762
2016 Hong AL, Tseng Y, Cowley G, Jonas O, Cheah J, Doshi M, Kynnap B, Oy C, Keskula P, Kryukov G, Cima M, Langer R, Schreiber S, Root D, Boehm J, et al. Abstract PR04: Integration of CRISPR-Cas9, RNAi and pharmacologic screens identify actionable targets in a rare cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-Pr04  0.445
2016 Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26  0.539
2016 Hong AL, Cowley GS, Tseng Y, Cheah JH, Jonas O, Doshi MB, Kynnap BD, Oh C, Meyer S, Clemons P, Burger M, Vazquez F, Weir B, Kryukov GV, Church A, et al. Abstract B38: Developing a functional genomics platform to interrogate rare pediatric cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B38  0.488
2016 Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367  0.55
2016 Tashiro K, Klink R, Zetterval J, Diedrich V, Tseng Y, Bagchi A. Abstract 2663: Insights into the oncogenic basis of long non-coding RNA PVT1 in human cancer Cancer Research. 76: 2663-2663. DOI: 10.1158/1538-7445.Am2016-2663  0.801
2015 Tseng YY, Bagchi A. The PVT1-MYC duet in cancer. Molecular & Cellular Oncology. 2: e974467. PMID 27308428 DOI: 10.4161/23723556.2014.974467  0.766
2015 Tseng Y, Bagchi A. Abstract PR01: Long noncoding RNA PVT1 potentiates MYC in human cancers with 8q24 gain Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr01  0.797
2015 Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07  0.547
2015 Berger A, Kim E, Brooks A, Shrestha Y, Tseng Y, Wu X, Ilic N, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Doench J, et al. Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2015-957  0.382
2014 Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 512: 82-6. PMID 25043044 DOI: 10.1038/Nature13311  0.775
2012 Tseng Y, Beadnell T, Schwertfeger K, Bagchi A. Abstract 3288: A chromosome engineering mouse model to identify mechanisms by which duplication of 8q24 promotes human breast cancer Cancer Research. 72: 3288-3288. DOI: 10.1158/1538-7445.Am2012-3288  0.738
2010 Tseng Y, Schwertfeger KL, Bagchi A. Abstract 3272: Chromosome engineered mouse model for human 8q24 amplicon observed in breast cancer patients Cancer Research. 70: 3272-3272. DOI: 10.1158/1538-7445.Am10-3272  0.763
Show low-probability matches.